See the DrugPatentWatch profile for rebif
Is Rebif Still Used for RRMS?
Rebif (interferon beta-1a) remains an approved and available treatment for relapsing-remitting multiple sclerosis (RRMS), but it's no longer considered a first-line standard by most guidelines due to higher efficacy options like oral disease-modifying therapies (DMTs). The FDA initially approved it in 2002 for relapsing MS forms, including RRMS, based on trials showing reduced relapse rates by about 30% versus placebo.[1] It's administered subcutaneously three times weekly and continues to be prescribed, especially for patients unable to tolerate or access newer drugs.
How Do Current Guidelines Rank It?
The American Academy of Neurology (AAN) 2018 guidelines and 2021 updates classify high-efficacy DMTs (e.g., ocrelizumab, natalizumab) as preferred for active RRMS, placing injectables like Rebif in a moderate-efficacy tier for milder cases or as maintenance therapy.[2] The National Multiple Sclerosis Society echoes this, recommending Rebif for early or low-risk RRMS but prioritizing orals like fingolimod or teriflunomide to minimize injection burden and side effects.[3] European guidelines (EMA) similarly approve it but favor newer agents in high-disease-activity scenarios.
What Are Common Side Effects Driving Shifts Away?
Patients often report flu-like symptoms (up to 60% in trials), injection-site reactions, liver enzyme elevations, and depression risk, contributing to discontinuation rates around 20-30% within two years.[4] These factors push prescribers toward pill-based alternatives with better tolerability.
How Does Rebif Compare to Top Alternatives?
| Drug | Type | Efficacy (Annualized Relapse Rate Reduction) | Dosing | Key Drawback |
|------|------|---------------------------------------------|--------|-------------|
| Rebif | Injectable interferon | ~30% vs. placebo | 3x/week subcutaneous | Flu-like symptoms, injections |
| Ocrelizumab (Ocrevus) | Monoclonal antibody | ~46-47% vs. interferon | IV every 6 months | Infusion time, infection risk |
| Fingolimod (Gilenya) | Oral S1P modulator | ~48-54% vs. interferon | Daily pill | Cardiac monitoring needed |
| Siponimod (Mayzent) | Oral S1P modulator | ~50%+ in active RRMS | Daily pill | Liver tests required |
Rebif lags in head-to-head trials (e.g., BECOME study showed similar efficacy to glatiramer but more side effects).[5] Biosimilars aren't yet approved for interferon beta-1a in the US, keeping Rebif as the branded option.
When Might Doctors Still Choose Rebif?
It's selected for treatment-naive patients with low relapse rates, pregnancy planning (Category C, short half-life), or cost constraints—annual US list price around $60,000-$70,000, often covered by insurance.[6] Patent exclusivity ended in 2013 (no active US patents per DrugPatentWatch),[7] but no generics have entered due to manufacturing complexity.
What's the Outlook with Newer Treatments?
Ongoing trials test Rebif combinations (e.g., with siponimod), but approvals for next-gen orals and infusions have reduced its market share from ~10% in early 2000s to under 5% today.[8] Patient registries like MSBase show it stabilizes disease in select low-risk RRMS cases.
[1]: FDA Label, Rebif (2002, updated 2023). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103432s525lbl.pdf
[2]: AAN Guidelines (2018/2021). https://www.aan.com/Guidelines/Home/GuidelineDetail/1056
[3]: National MS Society DMT Tool. https://www.nationalmssociety.org/Treating-MS/Medications
[4]: EVIDENCE Study, Neurology (2009).
[5]: BECOME Trial, NEJM (2007).
[6]: GoodRx pricing data (2024).
[7]: DrugPatentWatch.com, Rebif patents. https://www.drugpatentwatch.com/p/tradename/REBIF
[8]: IQVIA market reports (2023).